Systematic review and meta-analysis of cervico-vaginal high-risk human papillomavirus prevalence in India prior to nationwide human papillomavirus vaccination Authors: Indira Adhikari, Ishu Kataria, Prince Bhandari, Mariam Siddiqui, Partha Basu, Priya Abraham, Irene Man, Iacopo Baussano Published: 2026 ABSTRACT BackgroundTo estimate the overall prevalence of high-risk human papillomavirus (HR HPV) and HPV16/18 among the women in general population in India. This information is needed as a baseline to evaluate the impact of recently introduced nationwide HPV vaccination, as indicated in the World Health Organization (WHO) framework for cervical cancer elimination.MethodsWe conducted a systematic review and meta-analysis of studies of cervico-vaginal HR HPV and HPV16/18 published from 2005 to 2024 among women with a representative sample size of least 100 from the general population. Searches were conducted in four online databases (PubMed, Embase, Web of Science, Google Scholar). We excluded studies conducted only among women with increased risk of HR HPV infection such as women diagnosed with cancer, with a history of hysterectomy, pregnant, living with HIV (Human immunodeficiency virus), and sex workers.ResultsWe identified 201 studies through database searches, of which 39 and 20 were included in the systematic review and meta-analysis respectively. Among these, 6 reported overall HR HPV prevalence, 9 reported HPV16/18 prevalence, and 5 reported both. The pooled overall HR HPV prevalence in India was 11.4% (95% CI 8.5–15.2; I2 = 96.6%) and the pooled HPV16/18 prevalence was 5.6% (95% CI 3.7–8.2; I2 = 96.8%). The 95% prediction interval for HR HPV prevalence ranged from 2.9 to 36.0%, and for HPV16/18 from 0.7 to 31.7%. These observed differences between the studies were mainly driven by the use of non-standardized HPV tests and some by geographical region.ConclusionsThis review provides the most comprehensive estimates of data on HR HPV prevalence in India. However, the insufficient data to monitor the impact of the HPV vaccination programme at the national level urges the need for public health authorities and policymakers in India to prioritize systematic data collection on HPV prevalence with standardized framework/protocol across India.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13690-026-01916-0. Text box 1. Contributions to the literature• Population-level HPV prevalence is essential to monitor the impact of HPV vaccination which is a keycomponent of WHO’s framework for cervical cancer elimination.• There is limited systematic documentation of HPV prevalence and distribution of carcinogenic HPV types in general population in India.• Standardized methodologies and protocols for HPV prevalence surveys are urgently needed to generate high-quality baseline data and to facilitate repeated surveys in vaccinated population for long-term monitoring and evaluation Text box 1. Contributions to the literature• Population-level HPV prevalence is essential to monitor the impact of HPV vaccination which is a keycomponent of WHO’s framework for cervical cancer elimination.• There is limited systematic documentation of HPV prevalence and distribution of carcinogenic HPV types in general population in India.• Standardized methodologies and protocols for HPV prevalence surveys are urgently needed to generate high-quality baseline data and to facilitate repeated surveys in vaccinated population for long-term monitoring and evaluation Background In India, approximately 128,000 new cases of cervical cancer and 80,000 related deaths occurred in 2022, accounting for approximately 20% of the global burden [1]. The absence of human papillomavirus (HPV) vaccination in national immunization program and limited coverage of cervical cancer screening [2] significantly contributes to a lifetime risk of cervical cancer among younger birth-cohorts. This could be further exacerbated due to population growth and longer life expectancy [3]. Such an increase in the burden of cervical cancer across India would put further strain on the limited economic and logistic resources, hindering efforts to implement comprehensive cervical cancer control programmes nationwide. To decrease the burden of cervical cancer, the Indian government in 2022 committed to introducing the HPV vaccination for girls aged 9–14 as part of the Universal Immunization Programme (UIP) [4]. The UIP will rely on the quadrivalent HPV vaccine- CERVAVAC, manufactured by the Serum Institute of India, which has been licensed by the country’s Drugs Controller General [5]. The licensing of CERVAVAC represents a significant step towards implementing a locally manufactured low-cost HPV vaccine nationwide. Monitoring and evaluation of this vaccination programme, as indicated in the World Health Organization’s (WHO) framework, will be a fundamental part of supporting the country’s cervical cancer elimination strategy [6]. A key indicator of this framework is reduction in HPV prevalence over time among the general population [6], which reflects the effectiveness of the vaccination program [7, 8]. Until now, there has been little systematic documentation on HPV prevalence and the distribution of carcinogenic HPV types across India [2, 9–11]. This lack of systematic documentation complicates the implementation and impact monitoring of national HPV vaccination programmes, preventing policymakers from making data driven decisions to ensure that cervical cancer prevention efforts are more impactful and equitable across the country. To address this gap due to methodological variation and limited population-based data, this study aimed to assess whether a consolidated estimate of HPV prevalence can be estimated using published data. We performed a systematic review and meta-analysis of the available literature to assess the prevalence of cervico-vaginal HR HPV and HPV16/18, in India prior to HPV vaccination, which could help inform policy to reduce the cervical cancer burden. Methods Search strategy and selection criteria For this review, we followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines [12] checklist (Supplementary, Appendix Table 1). We searched PubMed, Embase, Web of Science, Google Scholar, along with a manual search for references to include articles that might have been missed through electronic searches. Literature searches were conducted using a variety of terms, medical subject headings (MeSH), and key words such as: “HPV” OR “Human Papillomavirus” AND “India” AND “Prevalence”. Our detailed search strategy for each database is reported in the Supplementary file (Appendix Table A2). The search consisted of peer-reviewed publications from 1 January 2005 to 31 November 2024. We restricted our review to studies from 2005 and onwards as the global launch of first HPV vaccines in 2005 shifted the efforts in HPV surveillance from strategies to screening methods and testing technologies. The search included studies reporting cervico-vaginal prevalence data for HPV and/or HR HPV types among women with representative sample of general population; minimum sample size of 100. We included only baseline HPV prevalence data if the study was a cohort study. If two studies had used the same study population, we included only the study which reported the most suitable HR HPV prevalence data. We included only the HPV prevalence studies among unvaccinated/pre-vaccinated individuals and excluded all other among vaccinated individuals. We excluded all other studies conducted only among the specific high-risk population such as women diagnosed with precancerous lesions or cancer, those with a history of hysterectomy, pregnant women, women living with human immunodeficiency virus (HIV), women diagnosed with a sexually transmitted infection, or sex workers. Literature review and data extraction Titles and abstracts were reviewed independently by IA, IK, MS and PrB. Data was extracted by IA, IK, MS and PrB, working in pairs. Discrepancies were discussed among the co-authors. For data extraction, we designed a structured MS Excel sheet format (Supplementary Excel file) to ensure consistency. The information extracted included the following: study, first author, year of publication, year of study implementation, study population, state, city, location (urban or rural), region (East, West, North, South), type of HPV test used, age range of included women, sample size of the study by age, number of HPV positive women by age and HR HPV type. Additionally, we emailed corresponding authors of included articles that did not report age-stratified prevalence for HR HPV and HPV16/18 requesting access to these data if they were collected as part of the study. Corresponding authors were given two weeks to respond: a reminder was sent in case we received no response. The final data were reviewed and discussed with all co-authors to reach a consensus. All included studies were assessed for quality relevant to our review based on how closely the study population represented the general population. To this end, we used an adapted version (Appendix Table A3) of JBI’s critical appraisal tool for prevalence studies [13]. We categorized the study population based on their representativeness and sampling method into four different study quality (SQ) categories: A1 (general population based), A2 (hospital based – for other than gynaecological reasons/screening), B1 (B1-a & B1-b: women invited for cervical cancer screening-community based), and B2 (hospital based – for gynaecological reasons/screening). A detailed description of the study population is available in the Supplementary file (Appendix Figure F1). Data analysis In our data analysis, we included only studies which had reported HPV prevalence among women from the general population or with normal cytology. For this reason, if a study was rated SQ A1, A2, or B1-a, we considered the study population to be a representative sample of the general population and therefore included it in our analysis. On the other hand, if a study was categorized as SQ - B1-b or B2, it would only be included if the study population was women with normal cytology. If SQ - B1-b or B2 studies were among women without normal cytology, we did not include them in our final analysis (Appendix Figure F1). The validation status of the HPV tests used by the studies in our analysis was assessed and categorized as; ‘clinically validated’, ‘partially validated’, ‘in-house polymerase chain reaction (PCR) test’ and ‘not validated test’ by using the 2020 updated list [14] of suitable HPV tests fulfilling Meijer’s validation criteria [15]. In terms of prevalence data, even though we extracted data on any HPV prevalence, as the number of HPV types tested for and detected by each test varies across studies, to be consistent across studies, we focused on overall HR HPV (HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) and HPV16/18 prevalence in the meta-analysis. We used random-effects models to generate pooled estimates of HR HPV and HPV16/18 prevalence, along with their associated 95% confidence intervals (CIs) and prediction intervals (PIs). The PIs provide a range of highly probable values for the true estimates in future settings while CIs are useful in assessing the precision of pooled estimates. Reporting PIs together with true estimates and CIs is highly recommended, as they offer a more comprehensive interpretation of the evidence for future application [16]. Heterogeneity between studies was assessed by using I2 statistics. For any study with multiple entries, i.e. reporting HPV prevalence at different places within the same study, we kept the multiple outcomes in the model as they were from different groups of individuals with no overlapping [17]. We also performed the age-specific analysis to evaluate age-specific patterns of overall HR HPV and HPV16/18 prevalence. Sensitivity analysis was conducted to assess the possible sources of underlying heterogeneity across studies. We performed subgroup meta-analyses by region (East, West, North, South) and by urban/rural location. We also performed other subgroup meta-analyses by sample size (‘small = ≤ 400’, ‘moderate = 400–1000’, ‘large = ≥ 1000’), by study quality (SQ - A1, A2, B1-a/b, B2) and by the type of HPV test (‘Clinically validated’, ‘Partially validated’, ‘In-house (PCR test’, ‘Not validated’) to identify the source of variation in overall HR HPV and HPV16/18 prevalence between the studies. We did not evaluate publication bias in our study as we in general do not expect the magnitude of prevalence would influence the chances of an HPV prevalence study to be accepted for publication. All statistical analyses were performed using R software (version 4.4.0). Although the review was not prospectively registered in a public registry, we adhered to established systematic review guidelines (PRISMA) and a predefined internal protocol outlining the methodology. Results We identified 201 (Fig. 1) potentially eligible studies through database search. After removing duplicate studies and studies that did not meet our inclusion criteria, 39 studies [10, 18–55] were included in the systematic review (Table 1). A summary of study characteristics is presented in Table 1. The studies were conducted between 1999 and 2022 in different urban (21 studies) and rural (18 studies) areas of India. Most of these were from the northern (13 studies), eastern region (11 studies) and southern region (11 studies). There were only two studies from the western region and the other two were conducted in multiple regions (Table 1). The sample size in these studies ranged from 104 to 27,192 participants with ages ranging from 8 to 80 years. The reason for having such wider age range is that the study participants were women participating in an HPV prevalence survey and cervical cancer screening enrolled from community, hospitals or school. All studies except three [18–20] used cervical samples for HPV detection. We decided to include studies that utilized urine samples for HPV detection, as it has been demonstrated that detection of HPV in urine is comparably sensitive to HPV detection in cervical samples [56, 57]. The included studies used mostly a PCR based test, but most of them (n = 35) did not fulfil the Meijer’s validation criteria [15] (Table 1). Of the 39 included studies, only seven studies had used a clinically validated test, most of the other studies had used in-house PCR tests while five used non-validated commercial HPV tests (Table 1). Two studies using in-house PCR tests, however, had performed quality-control exercise [21, 22]. Table 1Descriptive characteristics of included studiesAuthor, YearRegion - city^Study population quality assessmentType of HPV testAge range (Years)Normal cytologyAny cytologySample sizeOverall HPV prevalence (%)HR-HPV prevalence (%)HPV 16/18 prevalence (%)SamplesizeOverall HPV prevalence (%)HR-HPV prevalence (%)HPV 16/18 prevalence (%)(1) Aggarwal et al. (2006) [26]North -ChandigarhB2⸸PCR, primers for 6, 11, 16, 18, 31 & 3319–7532139.5%NA7.4%47237.3%8.3%8.3%(2) Adsul et al. (2019) [27]South-KarnatakaB1-a⸸⸸⸸HC230–59NA473NA7.6%NA(3) Arora et al. (2005) [28]North – New DelhiB2⸸PCR, HPV16 & 18 specific primer20–60104NANA6.7%160NANA10%(4) Asiaf et al. (2012) [29]North –SrinagarB2⸸PCR, GP5+/GP6+, MY09/11, HPV16 &18 specific primer18–5716011.9%NANA21013.8%NA10.5%(5) Bhatla et al. (2008) [10]North – New DelhiB2⸸⸸PCR PGMY09/11, typing by Roche linear array30–744587.6%5.4%2.6%NA(6) Bhattacharya et al. (2018) [30]East-West BengalB2⸸PCR PGMY09/11, GP5+/6+, HPV16 & 18 specific primer26–7062936.1%NA28.1%68436.8%NA29.2%(7) Bhattacharya et al. (2024) [23]East-TripuraB2⸸PGMY09/11 PCR18–8012089.2%NA40.8%23690.7%NA48.0%(8) Dakshinamurthy et al. (2023) [31]South-Andhra PradeshB1-b⸸ PCR30–55NA103526.0%NANA(9) Datta et al. (2010) [32]North – New DelhiA1⸸⸸PCR PGMY9/11, HC2, reverse line blot assay16–24NA13008.0%7.2%3.5%(10) Dutta et al. (2012) [33]East - KolkataB1-b⸸PCR, GP5+/GP6+, MY09/11, HPV16 & 18 specific primer25–6523139.2%NANA25019.9%NANA(11) Franceschi et al. (2005) [34]South – Tamil NaduA1⸸⸸⸸GP5+/GP6 + PCR EIA, oligoprobe cocktails16–59179914.0%9.6%3.4%189116.9%12.5%4.6%(12) Garg et al. (2016) [35]North - ChandigarhB2*Qiagen kit, ⸸PCR for 16, 18, 31, 4520–26NA21419.0%16.8%13.5%(13) Ghosh et al. (2019) [36]South – KarnatakaA1⸸PCR, sequencing of L1 locus20–65NA110014.3%13.3%NA(14) Gupta et al. (2009) [37]North – New DelhiB2⸸PCR, MY09/11. 16, 18, 6 & 11 type specific probes18–4576916.6%NA11.2%NA(15) Gupta et al. (2021) [38]North – Madhya PradeshA2⸸PCR MY09/11. Type 16 specific primer15–547827.2%NANANA(16) Hussain et al. (2012) [19]North-DelhiA1⸸PCR MY09/118–17NA4583.3%NANA(17) Kashyap et al. (2013)$ [39]North –New DelhiB2⸸PCR PGMY9/1146–58NA230NANANA(18) Kaur & Kaur (2019) [40]North – PatialaB2⸸⸸⸸BD Onclarity HPV assay< 30–60+NA10023.0%NANA(19) Laikangbam et al. (2007) [41]East - ManipurB1-a⸸PCR MY09/11, HPV16 & 18 primer20–806726.7%NA3.3%6927.4%NA3.5%East - SikkimB1-a⸸PCR MY09/11, HPV16 & 18 primer19–7535911.1%NA3.9%41512.5%NA5.3%East- West BengalB1-a⸸PCR MY09/11, HPV16 & 18 primer14–80100711.6%NA7.8%111213.0%NA9.2%(20) Mittal et al. (2024) [42]East-DehradunB2*PCR (Rotor-Gene)30–65NA653NA4.9%2.1%(21) Muwonge et al. (2020) [22]OverallA1*Multiplex Type-Specific E7-Based PCR15–24NA148419.6%16.5%3.4%South-Tamil Nadu15–2420027%23.5%2%West- Maharashtra15–2418817.5%13.8%3.2%North-New Delhi15–2420024.5%18%3%#West-Gujarat15–245010%10%2%South-Telangana15–2424819.3%16.5%3.6%West-Maharashtra15–2440011.5%10%2%East-Sikkim15–2410015%11%4%East-Mizoram15–2410043%39%13%(22) Pankaj et al. (2024) [43]East-BiharB2*PCR, genotyping kit for HR types21–78938NA26.1%NA1439NA37.3%NA(23) Panta et al. (2024) [24]Uttarakhand-EastB1-a⸸PCR30–65NA975NA4.4%2.8%(24) Parvez et al. (2024) [44]East-Andaman IslandA1⸸PCR18–59NA10005.0%NANA(25) Parwez et al. (2022) [20]East-BiharA1⸸PCR, HPV16 & 18 specific primer17–52NA157NANA12.1%(26) Peedicayil et al. (2016) [21]South-Tamil NaduB1-a⸸PCR, PGMY primers, Roche line blot assay< 35–50NA8099.4%6.4%NA(27) Ramshankar et al. (2023) [45]SouthB1-a⸸⸸⸸Cobas 480030–69NA10,3755.7%NANA(28) Sarkar et al. (2011) [46]East-West BengalB2⸸PCR, HPV16 & 18 specific primer15–40+NA1106NANA9.1%(29) Sarma et al. (2015) [25]East-AssamB2⸸ PCR MY09/11, GP5+/6+, HPV16 & 18 specific primer15–552723.7%NA0.7%31011.9%NANA(30) Sarvesan et al. (2023) [47]MultipleB2⸸PCR MY09/1119–60+3345.4%NANANA(31) Sauvaget et al. (2011) [48]West-MaharashtraB1-a⸸⸸⸸HC-230–59NA27,192NA10.3%NA(32) Sowjanya et al. (2005) [49]South - HyderabadB1-b⸸⸸HC2 & PCR line blot assay30–46+NA186NA10.2%NA(33) Srivastava et al. (2012) [50](2005–2010) [50]North - VaranasiB2⸸PCR, GP5 + /GP6 +, MY09/1117–80NA23989.9%8.3%6.7%(34) Srivastava et al. (2014) [51]North - VaranasiB2⸸PCR MY09/11, GP5+/6+,specific primers for 16, 18, 31, 33, 3525–8010412.5%NANANA(35) Subramanian et al. (2021) [52]South – Tamil NaduB1-a⸸⸸⸸HC2 & Roche linear array test< 25–60NA1523012.7%NA(36) Suresh et al. (2021) [53]South – KeralaB1-b*Care HPV, MY09/11, GP5+/6+35–65NA2443NA2.0%NA(37) Sureshkumar et al. (2015) [18]South-EodeB1-a⸸PCR MY09/11,GP5+/6+, Type specific primers for 6, 11,16, 18 & consensus primers for 31, 33, 52, 5820–7047219.3%7.4%NANASouth-Namakkal3777.7%6.1%NANASouth-Salem8506.9%4.9%NANAOverall169910.5%5.9%NANA(38) Vinodhi et al. (2012) [54]South –Tamil NaduB2⸸PCR MY09/11, GP5+/6+, type 6, 11,16, 18 specific primers21–60+25730.3%NA15.6%NA(39) Vora et al. (2022) [55]West - AhmedabadB1-bPCR (details NA)30–45NA95633.5%25.9%NAIn the age group, (< ) means the minimum age not reported and (+) means the maximum age not reported# West-Gujarat in Muwonge et al. 2020 has sample size N = 50 (< 100), thus it was not included in the meta-analysis where the multilevel studies were treated as individual studies^ Study population quality assessment: A1-general population based, A2-hospital based – for other than gynaecological reasons/ screening, B1-a & B1-b: women invited for cervical cancer screening-community based, and B2-hospital based - gynaecological reasons/screening$ Empty row for Kashyap et al. as only HPV16 prevalence (not included here) is reported⸸⸸⸸ Clinically validated test for screening⸸⸸ Both In-house PCR and clinically validated test for screening⸸ In-house PCR*No clinical validation Table 1Descriptive characteristics of included studiesAuthor, YearRegion - city^Study population quality assessmentType of HPV testAge range (Years)Normal cytologyAny cytologySample sizeOverall HPV prevalence (%)HR-HPV prevalence (%)HPV 16/18 prevalence (%)SamplesizeOverall HPV prevalence (%)HR-HPV prevalence (%)HPV 16/18 prevalence (%)(1) Aggarwal et al. (2006) [26]North -ChandigarhB2⸸PCR, primers for 6, 11, 16, 18, 31 & 3319–7532139.5%NA7.4%47237.3%8.3%8.3%(2) Adsul et al. (2019) [27]South-KarnatakaB1-a⸸⸸⸸HC230–59NA473NA7.6%NA(3) Arora et al. (2005) [28]North – New DelhiB2⸸PCR, HPV16 & 18 specific primer20–60104NANA6.7%160NANA10%(4) Asiaf et al. (2012) [29]North –SrinagarB2⸸PCR, GP5+/GP6+, MY09/11, HPV16 &18 specific primer18–5716011.9%NANA21013.8%NA10.5%(5) Bhatla et al. (2008) [10]North – New DelhiB2⸸⸸PCR PGMY09/11, typing by Roche linear array30–744587.6%5.4%2.6%NA(6) Bhattacharya et al. (2018) [30]East-West BengalB2⸸PCR PGMY09/11, GP5+/6+, HPV16 & 18 specific primer26–7062936.1%NA28.1%68436.8%NA29.2%(7) Bhattacharya et al. (2024) [23]East-TripuraB2⸸PGMY09/11 PCR18–8012089.2%NA40.8%23690.7%NA48.0%(8) Dakshinamurthy et al. (2023) [31]South-Andhra PradeshB1-b⸸ PCR30–55NA103526.0%NANA(9) Datta et al. (2010) [32]North – New DelhiA1⸸⸸PCR PGMY9/11, HC2, reverse line blot assay16–24NA13008.0%7.2%3.5%(10) Dutta et al. (2012) [33]East - KolkataB1-b⸸PCR, GP5+/GP6+, MY09/11, HPV16 & 18 specific primer25–6523139.2%NANA25019.9%NANA(11) Franceschi et al. (2005) [34]South – Tamil NaduA1⸸⸸⸸GP5+/GP6 + PCR EIA, oligoprobe cocktails16–59179914.0%9.6%3.4%189116.9%12.5%4.6%(12) Garg et al. (2016) [35]North - ChandigarhB2*Qiagen kit, ⸸PCR for 16, 18, 31, 4520–26NA21419.0%16.8%13.5%(13) Ghosh et al. (2019) [36]South – KarnatakaA1⸸PCR, sequencing of L1 locus20–65NA110014.3%13.3%NA(14) Gupta et al. (2009) [37]North – New DelhiB2⸸PCR, MY09/11. 16, 18, 6 & 11 type specific probes18–4576916.6%NA11.2%NA(15) Gupta et al. (2021) [38]North – Madhya PradeshA2⸸PCR MY09/11. Type 16 specific primer15–547827.2%NANANA(16) Hussain et al. (2012) [19]North-DelhiA1⸸PCR MY09/118–17NA4583.3%NANA(17) Kashyap et al. (2013)$ [39]North –New DelhiB2⸸PCR PGMY9/1146–58NA230NANANA(18) Kaur & Kaur (2019) [40]North – PatialaB2⸸⸸⸸BD Onclarity HPV assay< 30–60+NA10023.0%NANA(19) Laikangbam et al. (2007) [41]East - ManipurB1-a⸸PCR MY09/11, HPV16 & 18 primer20–806726.7%NA3.3%6927.4%NA3.5%East - SikkimB1-a⸸PCR MY09/11, HPV16 & 18 primer19–7535911.1%NA3.9%41512.5%NA5.3%East- West BengalB1-a⸸PCR MY09/11, HPV16 & 18 primer14–80100711.6%NA7.8%111213.0%NA9.2%(20) Mittal et al. (2024) [42]East-DehradunB2*PCR (Rotor-Gene)30–65NA653NA4.9%2.1%(21) Muwonge et al. (2020) [22]OverallA1*Multiplex Type-Specific E7-Based PCR15–24NA148419.6%16.5%3.4%South-Tamil Nadu15–2420027%23.5%2%West- Maharashtra15–2418817.5%13.8%3.2%North-New Delhi15–2420024.5%18%3%#West-Gujarat15–245010%10%2%South-Telangana15–2424819.3%16.5%3.6%West-Maharashtra15–2440011.5%10%2%East-Sikkim15–2410015%11%4%East-Mizoram15–2410043%39%13%(22) Pankaj et al. (2024) [43]East-BiharB2*PCR, genotyping kit for HR types21–78938NA26.1%NA1439NA37.3%NA(23) Panta et al. (2024) [24]Uttarakhand-EastB1-a⸸PCR30–65NA975NA4.4%2.8%(24) Parvez et al. (2024) [44]East-Andaman IslandA1⸸PCR18–59NA10005.0%NANA(25) Parwez et al. (2022) [20]East-BiharA1⸸PCR, HPV16 & 18 specific primer17–52NA157NANA12.1%(26) Peedicayil et al. (2016) [21]South-Tamil NaduB1-a⸸PCR, PGMY primers, Roche line blot assay< 35–50NA8099.4%6.4%NA(27) Ramshankar et al. (2023) [45]SouthB1-a⸸⸸⸸Cobas 480030–69NA10,3755.7%NANA(28) Sarkar et al. (2011) [46]East-West BengalB2⸸PCR, HPV16 & 18 specific primer15–40+NA1106NANA9.1%(29) Sarma et al. (2015) [25]East-AssamB2⸸ PCR MY09/11, GP5+/6+, HPV16 & 18 specific primer15–552723.7%NA0.7%31011.9%NANA(30) Sarvesan et al. (2023) [47]MultipleB2⸸PCR MY09/1119–60+3345.4%NANANA(31) Sauvaget et al. (2011) [48]West-MaharashtraB1-a⸸⸸⸸HC-230–59NA27,192NA10.3%NA(32) Sowjanya et al. (2005) [49]South - HyderabadB1-b⸸⸸HC2 & PCR line blot assay30–46+NA186NA10.2%NA(33) Srivastava et al. (2012) [50](2005–2010) [50]North - VaranasiB2⸸PCR, GP5 + /GP6 +, MY09/1117–80NA23989.9%8.3%6.7%(34) Srivastava et al. (2014) [51]North - VaranasiB2⸸PCR MY09/11, GP5+/6+,specific primers for 16, 18, 31, 33, 3525–8010412.5%NANANA(35) Subramanian et al. (2021) [52]South – Tamil NaduB1-a⸸⸸⸸HC2 & Roche linear array test< 25–60NA1523012.7%NA(36) Suresh et al. (2021) [53]South – KeralaB1-b*Care HPV, MY09/11, GP5+/6+35–65NA2443NA2.0%NA(37) Sureshkumar et al. (2015) [18]South-EodeB1-a⸸PCR MY09/11,GP5+/6+, Type specific primers for 6, 11,16, 18 & consensus primers for 31, 33, 52, 5820–7047219.3%7.4%NANASouth-Namakkal3777.7%6.1%NANASouth-Salem8506.9%4.9%NANAOverall169910.5%5.9%NANA(38) Vinodhi et al. (2012) [54]South –Tamil NaduB2⸸PCR MY09/11, GP5+/6+, type 6, 11,16, 18 specific primers21–60+25730.3%NA15.6%NA(39) Vora et al. (2022) [55]West - AhmedabadB1-bPCR (details NA)30–45NA95633.5%25.9%NAIn the age group, (< ) means the minimum age not reported and (+) means the maximum age not reported# West-Gujarat in Muwonge et al. 2020 has sample size N = 50 (< 100), thus it was not included in the meta-analysis where the multilevel studies were treated as individual studies^ Study population quality assessment: A1-general population based, A2-hospital based – for other than gynaecological reasons/ screening, B1-a & B1-b: women invited for cervical cancer screening-community based, and B2-hospital based - gynaecological reasons/screening$ Empty row for Kashyap et al. as only HPV16 prevalence (not included here) is reported⸸⸸⸸ Clinically validated test for screening⸸⸸ Both In-house PCR and clinically validated test for screening⸸ In-house PCR*No clinical validation Descriptive characteristics of included studies East- West Bengal (33) Srivastava et al. (2012) [50] (2005–2010) [50] In the age group, (< ) means the minimum age not reported and (+) means the maximum age not reported # West-Gujarat in Muwonge et al. 2020 has sample size N = 50 (< 100), thus it was not included in the meta-analysis where the multilevel studies were treated as individual studies ^ Study population quality assessment: A1-general population based, A2-hospital based – for other than gynaecological reasons/ screening, B1-a & B1-b: women invited for cervical cancer screening-community based, and B2-hospital based - gynaecological reasons/screening $ Empty row for Kashyap et al. as only HPV16 prevalence (not included here) is reported ⸸⸸⸸ Clinically validated test for screening ⸸⸸ Both In-house PCR and clinically validated test for screening ⸸ In-house PCR *No clinical validation Fig. 1Study selection flow diagram Study selection flow diagram Among the 39 studies, eight studies were population and non-screening-based (rates as SQ - A1: 7, SQ-A2: 1) and 31 were screening-based (SQ-B1-a: 8, SQ-B1-b: 5, SQ-B2: 18) (Table 1). As described earlier, we considered the data reported by SQ-A1, A2 and B1-a studies to be representative of the general population whereas data reported by SQ-B1-b and B2 had to also include women with normal cytology to be representative, thus, out of 39 studies, 28 studies (17 among women with normal cytology, 11 SQ-A1/A2/B1-a) had representative HPV prevalence data (supplementary file, Appendix Figure F2) and were therefore included in the further analysis. Of these, 28 studies, 22 reported any HPV prevalence, 14 reported HPV16/18 prevalence, and 11 reported overall HR HPV prevalence (supplementary file, Appendix Figure F2 & F3). Among the data considered to be representative of general population, the prevalence of any HPV ranged from (3.3%-89.2%) [19, 23] whereas the prevalence of HR HPV ranged from (4.4%-39.0%) [22, 24]. The prevalence of HPV16/18 went from (1.0%-40.8%) [23, 25] (supplementary file, Appendix Figure F2). In the meta-analysis, only studies reporting HR HPV and HPV16/18 prevalence were included (Figure 2A & B). The pooled prevalence of HR HPV and HPV16/18 were 11.4% (95% CI 8.5-15.2; I2 = 96.6%) and 5.6% (95% CI 3.7-8.2; I2 = 96.8%) respectively (Figure 3A & B). The 95% PI for HR HPV prevalence ranged from 2.9 to 36.0%, and for HPV16/18 from 0.7 to 31.7%. Fig. 2(A). Map of overall HR HPV prevalence data availability in India. (B). Map of HPV16/18 prevalence data availability in India (A). Map of overall HR HPV prevalence data availability in India. (B). Map of HPV16/18 prevalence data availability in India Fig. 3(A) Overall HR HPV prevalence and (B), HPV16/18 prevalence among women with sample representative of general population (A) Overall HR HPV prevalence and (B), HPV16/18 prevalence among women with sample representative of general population The designations used and the presentation of the material in this article do not imply the expression of any opinion whatsoever on the part of WHO and the IARC about the legal status of any country, territory, city, or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. The designations used and the presentation of the material in this article do not imply the expression of any opinion whatsoever on the part of WHO and the IARC about the legal status of any country, territory, city, or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. For the age-specific analysis, there were only six studies reporting age-specific HR HPV prevalence data and four studies reporting age-specific HPV16/18 prevalence (Appendix Figure F4). Age-categories were converted to mid age value for age-specific analysis. The overall pattern of HR HPV and HPV16/18 prevalence did not increase or decrease consistently with age among the studies. In the subgroup urban and rural location, there were no significant differences (chi-squared = 0.01, p-value = 0.91) (Fig. 4A) in the pooled prevalence of HPV16/18 between urban (95% PI, 0.6–35.3) and rural location (95% PI, 0.5–38.6) (supplementary file, Appendix figure F5). However, in the regional subgroup analysis, in the pooled prevalence of HPV16/18 between the north 5.3% (95% PI, 1.4–17.7), south 4.6% (95% PI, 0.2–48.4), east 7.3% (95% PI, 0.5–56.8) and west regions 2.4%+ (95% PI, 0.1–43.1) (supplementary file, Appendix figure F6), the chi-square (8.13) value indicated statistically significant (p-value = 0.04) regional variation (Fig. 4B). That means some differences in the HPV16/18 prevalence could be due to regional differences, however, the wide PI and high I2 within each subgroup indicated that there may be some other underlying differences such as population characteristics or difference in study design and implementation. Fig. 4(A) HPV16/18 prevalence by urban/rural location and (B) HPV16/18 prevalence by region among women with sample representative of general population (A) HPV16/18 prevalence by urban/rural location and (B) HPV16/18 prevalence by region among women with sample representative of general population For overall HR HPV prevalence, urban/rural location and the region could not sufficiently explain the heterogeneity (Supplementary, Appendix Figure F7-F8) across studies. In another subgroup analysis by type of HPV test, significant (p < 0.0001) high heterogeneity was observed among the studies using either ‘in-house HPV tests’ or ‘clinically not validated’ HPV tests. Though non-significant, studies using clinically validated tests showed relatively moderate heterogeneity (I2 = 46.5%, p-value = 0.15) (Supplementary, Appendix Figure F9-F10). This suggests that some inconsistencies between the prevalence estimates across the studies are due to methodological variability by the type of HPV test used. The subgroup analysis by SQ (A1, A2, B1-a/b, B2) for overall HR HPV, there was significant variations between studies by SQ (chi-squared = 13.5, p-value = 0.001) whereas, for HPV16/18, there was no significant difference (chi-squared = 3.79, p-value = 0.15) by SQ (Supplementary file, Appendix Figure F11-F12). Similarly, no difference was observed between the studies by sample size (Supplementary file, Appendix Figure F13-F14). Discussion Our findings, in particular the wide heterogeneity across studies and the corresponding wide PIs, showed that the currently available data on HPV prevalence from different regions of India are not comparable to set a reliable baseline prevalence to assess the impact of the national HPV vaccination programme, launched in early 2026 [60], and to monitor progress towards cervical cancer elimination in the country. More specifically, while population-based studies using similar methodologies have been crucial for assessing the impact of vaccination [56], the different studies conducted over time across India and included in this meta-analysis were intrinsically highly heterogeneous. This heterogeneity arises not only from being conducted in different settings but also probably due to differences in the targeted source populations, study design, implementation, and sample testing procedures, which were not standardized and therefore not comparable [58]. The subgroup analysis by type of HPV test demonstrated that the use of in-house and non-validated HPV tests produces inconsistent prevalence estimates. The wider PI further confirmed that the studies conducted using such non-standardized HPV tests will have similar uncertainties in the estimation of HPV prevalence. Similarly, the regional subgroup analyses showed significant differences, but the wider PI reflected the uncertainty of true effect of new study. Other subgroup analyses by urban/rural setting, quality of study and sample size could not account for the high heterogeneity observed. Furthermore, available data were also insufficient to identify a clear age-specific pattern for HR HPV prevalence. In summary, based on available data, the expected prevalence (with 95% probability) across India for HR HPV and HPV16/18 would range from 2.9% to 36.0% (pooled prevalence = 11.4%) and from 0.7% to 31.7% (pooled prevalence = 5.6%), respectively. The uncertainty of these estimates, primarily driven by the use of non-validated/in-house HPV tests, was therefore too great to define an operational baseline prevalence to monitor the impact of HPV vaccination in India. The main strength of our study is the comprehensive methodology applied to identify studies with data representative of women from the general population. Consequently, we excluded studies that recruited women with known cervical abnormality to ensure that our findings accurately reflect the represented demographic. However, if a study was population-based, we included data from any women, irrespective of their cytological status. We also specifically excluded studies focusing on selected subgroups of the general population such as specific tribal populations, sex workers or women living with HIV. These stringent criteria were designed to minimize the probability of including studies recruiting women with an overall increased risk of HPV infection compared to the general population [2]. Of note are earlier systematic reviews and meta-analyses on prevalence of HPV infection among women with normal cytology [2] and among Asian women [11] which were not restricted to focus on HR HPV types, and therefore their estimates obtained for India are incomparable to our study. The reported findings should be interpreted considering the following limitations: (a) we included HR HPV prevalence data from only 13 states and one union territory out of 28 states and eight union territories in India (based on our inclusion criteria), hence the study population (N = 38,179) included in our meta-analysis is not representative of the whole of India, and (b) the presence of substantial between-study heterogeneity limits the relevance and direct applicability of generated pooled estimates for informing national cancer control and prevention policies. In summary, our review provides the most updated estimates from women representing the general population in India by geographical region and concludes that the currently available data are insufficient to define a baseline HPV prevalence to effectively monitor the impact of a vaccination programme at the national level. Monitoring HPV prevalence is a key component of the WHO’s current framework to assess the progress towards cervical cancer elimination [6]. Our findings underscore the urgent need for public health authorities and policymakers in India to prioritize systematic data collection on HPV prevalence as an essential step for the nationwide vaccination programme. This will provide them with the essential information to manage and adapt cervical cancer elimination policies [59]. It is crucial to establish a standardized framework for HPV testing across all regions. This should include training for healthcare providers in sample collection, storage and transfer, and use of validated HPV tests as well as validation of in-house PCR tests for reproducibility and accuracy. Having a standardized methodology and protocol for HPV prevalence surveys are not only critical to generate consistent, high-quality baseline data but also to ensure the feasibility of repeated surveys in vaccinated population for long-term monitoring and evaluation. Additionally, integrating HPV prevalence monitoring to country’s health management information system will allow for public health authorities and policymakers to utilize real-time evidence-based data for effective cancer prevention and control efforts in India. Supplementary Information Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2